Arkansas is currently home to 660 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, Springdale, Arkansas
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: Arkansas Children's Research Institute, Little Rock, Arkansas
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Neuroblastoma
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.
NCT06493578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/16/2024
Locations: Clinical Trial Institute of Northwest Arkansas, LLC, Fayetteville, Arkansas
Conditions: Non-segmental Vitiligo
Register for Updates
VIA Disc NP Registry 3.0
NCT06345690
Recruiting
Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Mocek Spine, Little Rock, Arkansas
Conditions: Discogenic Pain, Back Pain, Back Pain, Low
Register for Updates
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03911505
Recruiting
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
09/16/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Pompe Disease (Late-onset)
Register for Updates
Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach
NCT05980260
Recruiting
This clinical trial will help us learn more about how to best care for babies with Neonatal Opioid Withdrawal Syndrome, also called NOWS. Babies with NOWS often have tremors, a hard time sleeping, excessive crying, and trouble feeding. Some babies that have NOWS need medicine. Doctors have two ways of providing medicine that are widely used today: 1. Scheduled opioid taper approach. The baby gets medicine at regular times. As symptoms get better, the amount of medicine the baby gets decreases u... Read More
Gender:
ALL
Ages:
Between 1 hour and 48 hours
Trial Updated:
09/13/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Neonatal Opiate Withdrawal Syndrome
Register for Updates
Encore PFO Closure Device - The PerFOrm Trial
NCT05537753
Recruiting
The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when compared to any investigator chosen FDA-approved PFO closure device.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
09/11/2024
Locations: Arkansas Cardiology, Little Rock, Arkansas
Conditions: Patent Foramen Ovale, Cryptogenic Stroke
Register for Updates
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
NCT05462145
Recruiting
This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/11/2024
Locations: St. Bernards Medical Center, Jonesboro, Arkansas
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
NCT05446272
Recruiting
DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.
Gender:
ALL
Ages:
Between 0 days and 9 weeks
Trial Updated:
09/09/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Extubation Failure, Bronchopulmonary Dysplasia, Death
Register for Updates
Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
NCT05403385
Recruiting
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Highlands Oncology Group, Fayetteville, Arkansas
Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Register for Updates
Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial).
NCT04372953
Recruiting
Premature babies often need help immediately after birth to open their lungs to air, start breathing and keep their hearts beating. Opening their lungs can be difficult, and once open the under-developed lungs of premature babies will often collapse again between each breath. To prevent this nearly all premature babies receive some form of mechanical respiratory support to aid breathing. Common to all types of respiratory support is the delivery of a treatment called positive end-expiratory pres... Read More
Gender:
ALL
Ages:
Between 23 weeks and 28 weeks
Trial Updated:
09/02/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Lung Injury, Preterm Birth
Register for Updates